HSIC Stock Analysis — Henry Schein
Sector: Healthcare Distribution
AI Verdict
HSIC trades at 15.0x next year's earnings with explosive EPS growth expected, so it's cheap for the growth on offer, but the overbought RSI means the next move could be a sharp correction if expectations slip.
Competitive Moat
Henry Schein operates as a distributor of dental and medical supplies, leveraging exclusive supplier relationships and integrated practice management software to lock in clinics and practitioners. Its scale and logistics network create switching costs for customers who rely on bundled supply and tech solutions.
Summary
HSIC's forward P/E of 15.0x with expected 75.7% EPS growth makes it a standout among healthcare distributors.
Where It Stands
The stock is up 31.53% over the past year, trades at 15.0x next year's earnings (well below the healthcare sector median of 22x), and its RSI of 75.3 signals overbought territory.
Key Metrics
- RSI: 75.3 — Overbought
- Trailing P/E: 26.4x
- Forward P/E: 15.0x
- PEG Ratio: 0.36
- Earnings Growth: +0.8%
- Revenue Growth: +0.1%
- Market Cap: $10.1B
- 1-Year Return: 31.53%
- 52-Week High: $92.18
- 52-Week Low: $61.95
Analyst Consensus
14 Buy · 10 Hold · 1 Sell (25 analysts)
Bull Case
With analysts forecasting 75.7% EPS growth and a forward P/E of just 15.0x, you're paying a low price for a big earnings jump if those numbers hold up.
Bear Case
An RSI of 75.3 means the stock is overbought—if it reverts to a neutral RSI, a 10–15% pullback would erase much of the recent 31.53% gain.
Catalyst to Watch
Watch for quarterly earnings—if EPS growth approaches the forecasted 75.7%, the low forward P/E could quickly look too cheap.